NeoGenomics (NEO) Tops Q1 EPS by 10c; Guides for FY16 Adjusted Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains
April 27, 2016 7:00 AM EDTFT. MYERS, Fla., April 27, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2016.
First Quarter 2016 Highlights:
159% increase in consolidated revenue to a record $59.7 million 442% increase in consolidated Adjusted EBITDA(1) to record $8.2 million 175% increase in consolidated clinical genetic testing volume(2) Adjusted Diluted EPS(1) of $0.03 per share and Diluted EPS of ($0.07) per shareConsolidated Revenue for the fourth quarter was $59.7... More
